PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

Westerink, L.; Nicolai, J.; Samuelsen, C.; Griebsch, I.; Postma, M.

doi:10.1016/j.jval.2019.09.383

PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS

L. Westerink, J. Nicolai, C. Samuelsen, I. Griebsch, M. Postma

L. Westerink

NobleIDNI9P95W83R29S57

Type:Journal Article

Claim Your Authorship

Sign in to see the full record

Creating an account is free.

Create an account

For data access, contact info@nobleid.org.

PCN187 BUDGET IMPACT OF SEQUENTIAL TREATMENT WITH AFATINIB FOLLOWED BY OSIMERTINIB VERSUS FIRST-LINE OSIMERTINIB IN NON-SMALL-CELL LUNG CANCER PATIENTS WITH COMMON EGFR MUTATIONS IN THE NETHERLANDS | NobleID